EGFR and non-small cell lung carcinoma: In TKIs-naive patients, a combinatorial approach has been tested in phase 1/2 KEYNOTE-021 study, where NSCLC patients were treated with pembrolizumab and one of the EGFR inhibitors: erlotinib (cohort E, n = 12) or gefitinib (cohort F, n = 7).